Academic Exchange | Visit to Hangzhou Institute of Medicine Chinese Academy of Sciences: Exploring New Frontiers in AI Antibody Design

During the exchange, Dr. Wang focused on epitope-specific de novo antibody design, introducing the technical background, core concepts, and applied explorations of AI-driven antibody design. For traditional antibody discovery approaches, certain targets — including those with low immunogenicity, cryptic epitopes, or conformation-dependent structures — often face challenges in candidate acquisition and epitope control. Addressing these R&D challenges, Clickmab explores the use of generative AI algorithms, combining antigen structures with target epitope information for computational antibody design, offering a new technical pathway for epitope-specific antibody discovery. Building on this technical exploration, Clickmab further developed its proprietary Click.mAb. AI antibody R&D platform. The platform integrates AI design, structural analysis, and engineering optimization capabilities, covering the entire process from target epitope analysis and candidate antibody generation to affinity optimization, humanization, and developability assessment — helping research teams advance antibody R&D more systematically.

Looking ahead, Clickmab will continue to explore the deep integration of AI and life science R&D, continuously optimizing algorithm models and platform capabilities to drive AI from technical demonstrations to real R&D applications, providing research teams with more efficient and precise antibody design solutions. If you are also interested in how AI empowers antibody drug R&D, we welcome you to reach out for further discussion and jointly explore the new possibilities of biomedical R&D.